home > epc > summer 2019 > fit for purpose
European Pharmaceutical Contractor

Fit for Purpose

Clinical trials remain the gold standard for establishing safety and efficacy for medical products, but results generated from a carefully structured protocol do not reflect real-world settings and may not be generalisable to scenarios at home and in the clinic. Physicians, their patients, and payers each have a stake in ensuring that results from clinical studies determine the most complete benefit-risk profile possible; as a result, interest in developing real-world evidence (RWE) is on the rise. Increased attention to regulatory applications of RWE is a response to regulatory authorities issuing guidelines for trial designs that include randomised pragmatic trials, as well as studies that employ non-interventional RWE to test effectiveness and safety (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the authors

Marni Hall, Vice President of Clinical Evidence in the Center of Advanced Evidence Generation at IQVIA, leverages her expertise in regulatory science, drug safety, and patient centricity to provide scientific oversight and strategic direction on the expanded use of RWE. Marni has two decades of experience in both science and policy and has been responsible for developing data standards, sourcing, and analysing datasets, overseeing the delivery of commercial research programmes and the execution of an agenda for use of patient-generated health data in clinical and regulatory decision making.

Nicola Stanislaus PhD, Director of Project Management (Europe) at IQVIA Biotech, is responsible for overseeing study management within IQVIA Biotech’s oncology team. Nicola has more than 15 years’ experience in the conduct and oversight of oncology clinical trials and provides strategic leadership, oversight, training, and ongoing evaluation and support to the clinical operations group.

Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase AirBridgeCargo Airlines (ABC), one of the leaders in transportation of pharmaceutical products by air, and Zurich-based cold-chain ULD manufacturer SkyCell have sealed their partnership for the lease of all types of SkyCell containers to meet the demand for evolving volumes of passive pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019 YOY and demonstrated a two-fold increase.
More info >>

White Papers

RSSL introduces same-day mycoplasma testing service in UK


Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement